Beam Therapeutics Reports Wider-Than-Expected Q3 Net Loss as Revenue Falls
Story updates
12:22:00 PM UTC
SquawkNews
*--Earnings Flash (BEAM) Beam Therapeutics Posts Q3 Loss $1.28 a Share, vs. FactSet Est of $1.15 Loss
Related stories
Lacroix Group Schedules 2026 Annual Revenue Release
Lacroix Group will release its 2026 annual revenue.
M impact | EQUITY | Nov 03, 2026, 04:40 PM UTC
Lacroix Group Launches Share Buyback Program of Up to €28.97 Million
Lacroix Group launched a share buyback program of up to €28.97 million.
L impact | EQUITY | Nov 03, 2026, 04:40 PM UTC
Lacroix Group Announces Annual 2026 Revenue Publication
Lacroix Group says it will publish its annual 2026 revenue. The publication timing is not provided.
M impact | EQUITY | Nov 03, 2026, 04:40 PM UTC
Lacroix Group Launches Share Buyback Program for Up to 10% of Capital
Lacroix Group has launched a share buyback program covering up to 10% of its capital.
M impact | EQUITY | Nov 03, 2026, 04:40 PM UTC
Neurocrine Biosciences Reports Strong Q3 Results, RBC Says
RBC described Neurocrine Biosciences' Q3 results as strong.
M impact | EQUITY | Nov 03, 2026, 04:39 PM UTC
US API Gasoline Stock Change
L impact | EQUITY | Nov 03, 2026, 04:38 PM UTC